发明名称 |
SOLUBLE MUTANT CTLA4 AND USES THEREOF |
摘要 |
FIELD: immunobiotechnology. ^ SUBSTANCE: invention relates to soluble CTLA4, which represents mutant variant of wild type CTLA4 and conserves binding ability to CD80 and/or CD86. Molecules of soluble CTLA4 have the first amino acid sequence containing extracellular CTLA4 region, which includes some mutant amino acid residues in S25-R33 region and M97-G107 region. According the present invention mutant molecules also may include second amino acid sequence, enhancing solubility of mutant molecule. Nucleic acid (NA) molecules encoding said CTLA4 and including NA-vectors also are described. Invention also relates to method for production of mutant CTLA4 and uses thereof in controlling of interaction between T-cell and CD80 and/or CD86-positive cell; suppression of graft-versus-host reaction; and treatment of immune system diseases. Soluble mutant CTLA4 according to present invention binds to CD80 and/or CD86 antigen with higher avidity than wild type CTLA4 or non-mutant CTLA41g. ^ EFFECT: new preparation for treatment of immune system diseases. ^ 65 cl, 19 dwg, 2 tbl, 2 ex |
申请公布号 |
RU2283847(C2) |
申请公布日期 |
2006.09.20 |
申请号 |
RU20020131588 |
申请日期 |
2001.05.23 |
申请人 |
BRISTOL-MAERS SKVIBB KOMPANI |
发明人 |
PICH ROBERT DZH.;NAEMURA DZHOZEF R.;LINSLI PITER S.;BAJORAT JURGEN |
分类号 |
C07K14/705;C12N15/09;A61K38/00;A61K38/02;A61K45/00;A61P37/00;A61P37/06;C07K;C07K14/47;C07K16/00;C07K19/00;C12N5/10;C12N15/12;C12N15/63;C12P21/00;C12P21/02;C12Q1/02;G01N33/68 |
主分类号 |
C07K14/705 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|